Interviews

Medbridge is working to refine remote therapeutic monitoring, or RTM, to transform physical therapy and enhance patient care.

In-network ambulatory surgery centers are cheapest, while out-of-network hospital outpatient departments nearly double costs, says Xiaoxi Zhao, PhD.

Using artificial intelligence (AI) to specialize treatment for patients with different kinds of cancer can be a boon to clinicians looking to personalize their care.

Michael Hassett, MD, MPH, discusses the rise of oral therapeutics in breast cancer care, emphasizing patient support, education, and overcoming financial barriers for better outcomes.

Breast cancer is the most researched disease globally, yet there are still significant gaps in equity and access to care and treatments.

A new analysis from Komodo Health pinpointed significant disparities by age and insurance in antibody-drug conjugate (ADC) treatment rates for metastatic breast cancer.

Lisa Taylor-Swanson, PhD, explains how including Indigenous and Hispanic women in conversations around menopause care helps fine-tune interventions.

New methods of testing tissue and plasma beyond next-generation sequencing (NGS) could be used to deliver the best therapeutic options for patients with cancer.

Marcus Flores, PharmD, BCPS, BCOP, discusses the vital role of pharmacists in multidisciplinary cancer care, exploring collaboration, patient-centered strategies, and AI.

Nicoletta Colombo, MD, PhD, of the University of Milan-Bicocca, discussed the rationale behind paclitaxel with bevacizumab and pembrolizumab in ovarian cancer.

Online health discussions can influence patient behaviors, but misinformation spreads easily. Khush Kharidia, MD, UT Southwestern, explains how creator credibility impacts cholesterol-related health information.

Jo Varshney, PhD, DVM, discusses how artificial intelligence–powered simulations speed drug approvals and reduce clinical trial risk.

Experts discuss how topical therapies effectively manage atopic dermatitis in pediatric patients, enhancing outcomes and addressing unique challenges.

Kimberly Westrich, MA, discusses how patient engagement can revolutionize health care decision-making and break down barriers to accessing necessary medicines and care.

Rocatinlimab shows real-world promise for moderate to severe AD, enhancing treatment efficacy and reducing steroid reliance, explains Emma Guttman-Yassky, MD, PhD.

Harry Travis, BS Pharm, MBA, explores how artificial intelligence (AI) can revolutionize pharmacy workflows for sustainable productivity gains.

Geni Tunstall, JD, discusses how pharmacy benefit manager reforms, Medicaid changes, and the MAHA initiative may impact managed care pharmacy operations.

Brigid Groves, PharmD, MS, discusses the importance of using trustworthy sources so that pharmacists can support communities with accurate information.

Chelsea Renfro, PharmD, discusses the importance of rigorous study designs to establish medication efficacy.

Real-world evidence helps pharmaceutical companies and payers communicate more effectively.

Marc S. Raab, MD, PhD, discusses the different ways that combination therapy that includes teclistamab can benefit patients with multiple myeloma.

Discover how the Hearing Loss Association of America advocates for hearing loss awareness and hearing health integration through a dialogue with Barbara Kelley, executive director.

Experts at CHEST 2025 highlight rising costs, insurance complexity, and workforce shortages as major barriers to health care access in the US.

Vaccine awareness, safety, and addressing misinformation are all important to improve adherence and public health outcomes, said Kristina Crothers, MD.

Ken Cohen, MD, FACP, discusses how new cognitive assessment tools are improving Alzheimer disease diagnosis.

Preclinical data suggest a possible synergistic interaction between estrogen and GLP-1 signaling, explains Regina Castaneda, MD.

US safety data show that elinzanetant caused few adverse events and no new liver-related concerns in women, James Simon, MD, explains.

Artificial intelligence models may advance clinical trial design and enrollment to improve trial success and patient outcomes.

Hormonal shifts drive fat redistribution, muscle loss, and bone decline—all risk factors for cardiovascular disease in women, says Brooke Aggarwal, EdD.

Belantamab mafodotin provides a community-friendly BCMA-directed therapy option for relapsed/refractory myeloma, says Hearn Jay Cho, MD, PhD.